Clinical trial

A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer

NCT01812746

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2013-04-01

PhasePHASE2

Study timeline

Study start (unknown)2013-04-01Date precision: month

Registry last updated2016-04-15

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

CRPCunresolved

Prostate Cancerunresolved

Interventions

BIND-014DRUG

Sponsors & collaborators

BIND Therapeuticslead sponsor

Mapped research locations

New YorkNew York, United States1 Los AngelesCalifornia, United States1 NashvilleTennessee, United States1 San FranciscoCalifornia, United States1 ClevelandOhio, United States1 Ann ArborMichigan, United States1 Chapel HillNorth Carolina, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01812746 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.